| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/27/2001 | US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 12/27/2001 | US20010056081 Treatment of cerebrovascular disease |
| 12/27/2001 | US20010055782 Enzymatic protein for use in the diagnosis, treatment and prevention of alzheimer's disease and nervous system disorders |
| 12/27/2001 | US20010055630 Compostion and methods for treating alzheimer's disease and other amyloidoses |
| 12/27/2001 | US20010055614 Osmosis dosage form |
| 12/27/2001 | US20010055613 Oral pulsed dose drug delivery system |
| 12/27/2001 | US20010055571 Controlled unit dose to induce sedative-anxiolytic physiological response in the mammal, comprising lorazepam, nonaqueous, organic liquid solvent carrier and a preservative, in a manually actuated spray device |
| 12/27/2001 | US20010055569 Nasal drug delivery composition |
| 12/27/2001 | CA2814737A1 Transgenic animal model of neurodegenerative disorders |
| 12/27/2001 | CA2414085A1 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 12/27/2001 | CA2414020A1 Methods and compositions for the treatment of peripheral artery disease |
| 12/27/2001 | CA2414015A1 Human receptors |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413986A1 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | CA2413974A1 Neuroactive peptides for treatment of hypoxia and related conditions |
| 12/27/2001 | CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | CA2413754A1 Canine hepatocyte growth factor |
| 12/27/2001 | CA2413556A1 Positively-charged peptide nucleic acid analogs with improved properties |
| 12/27/2001 | CA2413454A1 A g-protein coupled receptor |
| 12/27/2001 | CA2413435A1 A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists |
| 12/27/2001 | CA2413324A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/27/2001 | CA2413277A1 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) |
| 12/27/2001 | CA2412905A1 Improved injectable dispersions of propofol |
| 12/27/2001 | CA2412636A1 Method of treating cardiovascular disease using rapamycin |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2412199A1 Compositions containing 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivatives for the prevention and treatment of neurodegenerative diseases |
| 12/27/2001 | CA2412188A1 3-azabicyclo¬3.1.0|hexane derivatives useful in therapy |
| 12/27/2001 | CA2412141A1 Indole derivatives useful for the treatment of cns disorders |
| 12/27/2001 | CA2411865A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 12/27/2001 | CA2411756A1 Mutation associated with epilepsy |
| 12/27/2001 | CA2411585A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | CA2411553A1 New use of angiotensin ii antagonists |
| 12/27/2001 | CA2411255A1 Novel compounds |
| 12/27/2001 | CA2411100A1 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 12/27/2001 | CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | CA2410447A1 Bis-arylsulfones |
| 12/27/2001 | CA2410208A1 Systems and methods for treating a mucosal surface |
| 12/27/2001 | CA2409781A1 Phosphodiesterases |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/27/2001 | CA2409776A1 G-protein coupled receptors |
| 12/27/2001 | CA2407847A1 Transgenic animal model of neurodegenerative disorders |
| 12/26/2001 | CN1328560A [1,2,4] triazolo [1,5-c] pyrimidine derivatives |
| 12/26/2001 | CN1328559A CRF receptor antagonists and methods relating thereto |
| 12/26/2001 | CN1328554A Eletriptan hydrobromide monohydrate |
| 12/26/2001 | CN1328553A 3-Tetrahydropyridin-4-yl indoles for treatment of psychotic disorders |
| 12/26/2001 | CN1328552A Pyrimidone derivatives |
| 12/26/2001 | CN1328550A Oxazole compounds as prostaglandin E2 agonists or antagonists |
| 12/26/2001 | CN1328549A Substituted benzo [de] isoquinoline-1,3-diones |
| 12/26/2001 | CN1328538A 2,4-pentadienoic acid derivatives having selective activity for retinoid X(RXR) receptors |
| 12/26/2001 | CN1328470A Chemokine receptor peptide vaccines for treatment and prevention of diabetes |
| 12/26/2001 | CN1328459A Oral dosage formulations comprising (2S, 3S, 5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and effective stabilizing amount of alginic acid |
| 12/26/2001 | CN1328455A Use of N-substituted azabicycloalkane derivatives for treating diseases of central nervous system |
| 12/26/2001 | CN1328454A Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 12/26/2001 | CN1328453A Pharmaceutical composition comprising combination of dextro-and laevo-isomers of sotalol |
| 12/26/2001 | CN1328448A Fentanyl composition for treatment of acute pain |
| 12/26/2001 | CN1328417A Compositions and methods for treatment of mitochondrial diseases |
| 12/26/2001 | CN1327852A Chinese medicine for treating coronary heart disease, reducing blood fat and improving sleep and its preparing process |
| 12/26/2001 | CN1327813A Chinese medicine for nourishing vital essence and refreshing brain |
| 12/26/2001 | CN1327802A Health-care liquid for treating syndrome after dropping drug and preparing process thereof |
| 12/26/2001 | CN1327799A Mixture of white pepper and borneol and its application |
| 12/26/2001 | CN1327793A Pyrrolo-triazine and pyrimidine compounds |
| 12/26/2001 | CN1076624C Nasally administrable compositions |
| 12/26/2001 | CN1076608C Chinese medicine for treating anxiety neurosis |
| 12/25/2001 | US6333341 Tumor necrosis factor, antiinflammatory agents and analgesics |
| 12/25/2001 | US6333340 Sulfonamides with oxo, ester or amide groups for vision defects and cognition activators |
| 12/25/2001 | US6333339 3-Benzylpiperidine |
| 12/25/2001 | US6333336 Pyrazolo-pyridine derivatives as ligands for GABA receptors |
| 12/25/2001 | US6333328 Serotonin 5-HT3 receptor partial activator |
| 12/25/2001 | US6333325 Method of treating cytokine mediated diseases or conditions |
| 12/25/2001 | US6333310 NGF variants |
| 12/25/2001 | US6333168 Cloning, expression and uses of dorsalin-1 |
| 12/25/2001 | US6333161 Assaying a test ligands ability to bind a central nervous system receptor by incubation the ligand with mutant cells that produce a kainate-binding excitatory amino acid receptor and determining the extent of binding |
| 12/25/2001 | US6333044 For therapy of inflammation and pain of a traumatic or pathologic origin |
| 12/25/2001 | US6333037 Methods for treating pain with a modified neurotoxin |
| 12/25/2001 | US6333035 Administering monoclonal antibody against a human t-cell leukemia virus-derived transcription activating factor p40tax-induced cell membrane glycoprotein of 34 kda (gp34) in an amount effective for treating rheumatoid arthritis |
| 12/25/2001 | US6333033 Autoantibody inhibitors |
| 12/25/2001 | CA2052424C 2-(4-piperidinyl)-1h-pyrido¬4,3-b|indol-1-ones and related compounds, intermediates and a process for their preparation |
| 12/21/2001 | CA2351129A1 Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/21/2001 | CA2351125A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/20/2001 | WO2001096878A2 Marker for neurodegerative diseases and its use in drug screening |
| 12/20/2001 | WO2001096603A2 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | WO2001096598A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF |
| 12/20/2001 | WO2001096567A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/20/2001 | WO2001096553A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/20/2001 | WO2001096547A2 Human kinases |
| 12/20/2001 | WO2001096546A2 Protein phosphatases |
| 12/20/2001 | WO2001096397A2 Cd154 variants and uses thereof |
| 12/20/2001 | WO2001096372A2 Zinc transporters proteins and their use in medicinal preparations |
| 12/20/2001 | WO2001096369A1 Gluthione analogues and their use as antioxidants |
| 12/20/2001 | WO2001096364A2 Peptides that stimulate cell survival and axon regeneration |
| 12/20/2001 | WO2001096347A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD |
| 12/20/2001 | WO2001096337A1 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds |
| 12/20/2001 | WO2001096331A1 Lactam inhibitors of factor xa and method |
| 12/20/2001 | WO2001096330A2 Thrombin receptor antagonists |
| 12/20/2001 | WO2001096328A1 Indole derivatives useful for the treatment of cns disorders |
| 12/20/2001 | WO2001096311A2 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | WO2001096308A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| 12/20/2001 | WO2001096305A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096302A1 Piperidines for use as orexin receptor antagonists |
| 12/20/2001 | WO2001096289A1 Sulfonamide derivatives |